Home Neoplasma 2017 Neoplasma Vol.64, No.4, p.626-632, 2017

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.64, No.4, p.626-632, 2017

Title: BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma
Author: X. BAI, L. L. MAO, Z. H. CHI, X. N. SHENG, C. L. CUI, Y. KONG, J. DAI, X. WANG, S. M. LI, B. X. TANG, B. LIAN, L. ZHOU, X. Q. YAN, J. GUO, L. SI

Abstract: BRAF inhibitors substantially have impressive clinical efficacy in cutaneous melanoma. However, their role in acral and mucosal melanoma remains unclear. Records were reviewed of patients with metastatic or unresectable BRAF-mutant acral and mucosal melanoma hospitalized and administrated BRAF inhibitors during January 2011 and March 2016. Clinical data were collected to determine PFS, ORR, DCR, OS, and safety. Among 28 acral and 12 mucosal melanoma patients treated with BRAF inhibitors, median PFS were 3.6 (95%CI 3.0-6.4) and 4.4 (95%CI 0.8-12.7) months, median OS were 6.2 (95%CI 6.1-12.1) and 8.2 (95%CI 6.6-19.9) months; ORRs were 38.1% and 20.0%, DCRs were 81.0% and 70.0% in acral and mucosal melanoma, respectively. BRAF inhibitors were well tolerated. The most common adverse effects (AEs) were cutaneous and hematological. Grade 3/4 AEs were relatively rare. In conclusion, BRAF inhibitors have acceptable efficacy and good tolerance in BRAF mutant acral and mucosal melanoma.

Keywords: BRAF inhibitor, acral, mucosal, melanoma
Published online: 11-Jul-2017
Year: 2017, Volume: 64, Issue: 4 Page From: 626, Page To: 632

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.